Dopamine Turnover Increases in Asymptomatic LRRK2 Mutations Carriers
Identifieur interne : 000368 ( PascalFrancis/Checkpoint ); précédent : 000367; suivant : 000369Dopamine Turnover Increases in Asymptomatic LRRK2 Mutations Carriers
Auteurs : Vesna Sossi [Canada] ; Raul De La Fuente-Fernandez [Canada] ; Ramachandiran Nandhagopal [Canada] ; Michael Schulzer [Canada] ; Jessamyn Mckenzie [Canada] ; Thomas J. Ruth [Canada] ; Jan O. Aasly [Norvège] ; Matthew J. Farrer [États-Unis] ; Zbigniew K. Wszolek [États-Unis] ; Jon A. Stoessl [Canada]Source :
- Movement disorders [ 0885-3185 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Increase in dopamine (DA) turnover was found to occur early in symptomatic Parkinson's disease (PD) and to be functionally related to the dopamine transporter (DAT). The objectives of this study were to examine changes in DA turnover in the asymptomatic PD phase; to compare them with changes in other dopaminergic markers, and to investigate a possible relationship between DAT and DA turnover. Eight subjects from families at increased risk of PD due to LRRK2 mutation were investigated. Positron emission tomography imaging was performed with: 18F-fluorodopa to determine the effective DA distribution volume (EDV), the inverse of DA turnover, and the DA uptake rate Kocc, a marker of DA synthesis and storage; C-methylphenidate (MP, a DAT marker) and 11C-dihydrotetrabenazine (DTBZ, a VMAT2 marker) to estimate the binding potentials BPND_MP and BPND_DTBZ. On average, EDV showed the largest reduction from age-matched control values (42%) followed by BPND_MP (23%) and BPND_DTBZ (17%), whereas Kocc remained in the normal range for all subjects. No correlation was found between EDV and any other marker. DA turnover was found to be elevated in asymptomatic mutation carriers at increased risk of PD. Such change was determined to be larger than and statistically independent from changes observed with the other markers. These results support a compensatory role of increased DA turnover in presymptomatic disease and indicate that at this stage, in contrast to the symptomatic PD phase, increased turnover is not related to DAT.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:11-0065108Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dopamine Turnover Increases in Asymptomatic LRRK2 Mutations Carriers</title><author><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Physics and Astronomy, University of British Columbia</s1><s2>Vancouver British Columbia</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="De La Fuente Fernandez, Raul" sort="De La Fuente Fernandez, Raul" uniqKey="De La Fuente Fernandez R" first="Raul" last="De La Fuente-Fernandez">Raul De La Fuente-Fernandez</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Pacific Parkinson's Research Centre</wicri:noRegion></affiliation></author><author><name sortKey="Nandhagopal, Ramachandiran" sort="Nandhagopal, Ramachandiran" uniqKey="Nandhagopal R" first="Ramachandiran" last="Nandhagopal">Ramachandiran Nandhagopal</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Pacific Parkinson's Research Centre</wicri:noRegion></affiliation></author><author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Pacific Parkinson's Research Centre</wicri:noRegion></affiliation></author><author><name sortKey="Mckenzie, Jessamyn" sort="Mckenzie, Jessamyn" uniqKey="Mckenzie J" first="Jessamyn" last="Mckenzie">Jessamyn Mckenzie</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Pacific Parkinson's Research Centre</wicri:noRegion></affiliation></author><author><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>TRIUMF</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>TRIUMF</wicri:noRegion></affiliation></author><author><name sortKey="Aasly, Jan O" sort="Aasly, Jan O" uniqKey="Aasly J" first="Jan O." last="Aasly">Jan O. Aasly</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Neuroscience and Neurology, NTNU</s1><s2>Trondheim</s2><s3>NOR</s3><sZ>7 aut.</sZ></inist:fA14><country>Norvège</country><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation></author><author><name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Neuroscience, Mayo Clinic</s1><s2>Jacksonville, Florida</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Wszolek, Zbigniew K" sort="Wszolek, Zbigniew K" uniqKey="Wszolek Z" first="Zbigniew K." last="Wszolek">Zbigniew K. Wszolek</name><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Neurology, Mayo Clinic</s1><s2>Jacksonville, Florida</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Stoessl, Jon A" sort="Stoessl, Jon A" uniqKey="Stoessl J" first="Jon A." last="Stoessl">Jon A. Stoessl</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Pacific Parkinson's Research Centre</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0065108</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 11-0065108 INIST</idno><idno type="RBID">Pascal:11-0065108</idno><idno type="wicri:Area/PascalFrancis/Corpus">000351</idno><idno type="wicri:Area/PascalFrancis/Curation">000912</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000368</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000368</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dopamine Turnover Increases in Asymptomatic LRRK2 Mutations Carriers</title><author><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Physics and Astronomy, University of British Columbia</s1><s2>Vancouver British Columbia</s2><s3>CAN</s3><sZ>1 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Vancouver British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="De La Fuente Fernandez, Raul" sort="De La Fuente Fernandez, Raul" uniqKey="De La Fuente Fernandez R" first="Raul" last="De La Fuente-Fernandez">Raul De La Fuente-Fernandez</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Pacific Parkinson's Research Centre</wicri:noRegion></affiliation></author><author><name sortKey="Nandhagopal, Ramachandiran" sort="Nandhagopal, Ramachandiran" uniqKey="Nandhagopal R" first="Ramachandiran" last="Nandhagopal">Ramachandiran Nandhagopal</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Pacific Parkinson's Research Centre</wicri:noRegion></affiliation></author><author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Pacific Parkinson's Research Centre</wicri:noRegion></affiliation></author><author><name sortKey="Mckenzie, Jessamyn" sort="Mckenzie, Jessamyn" uniqKey="Mckenzie J" first="Jessamyn" last="Mckenzie">Jessamyn Mckenzie</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Pacific Parkinson's Research Centre</wicri:noRegion></affiliation></author><author><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>TRIUMF</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>6 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>TRIUMF</wicri:noRegion></affiliation></author><author><name sortKey="Aasly, Jan O" sort="Aasly, Jan O" uniqKey="Aasly J" first="Jan O." last="Aasly">Jan O. Aasly</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Neuroscience and Neurology, NTNU</s1><s2>Trondheim</s2><s3>NOR</s3><sZ>7 aut.</sZ></inist:fA14><country>Norvège</country><placeName><settlement type="city">Trondheim</settlement><region type="région" nuts="2">Trøndelag</region></placeName></affiliation></author><author><name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name><affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Neuroscience, Mayo Clinic</s1><s2>Jacksonville, Florida</s2><s3>USA</s3><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Wszolek, Zbigniew K" sort="Wszolek, Zbigniew K" uniqKey="Wszolek Z" first="Zbigniew K." last="Wszolek">Zbigniew K. Wszolek</name><affiliation wicri:level="2"><inist:fA14 i1="06"><s1>Department of Neurology, Mayo Clinic</s1><s2>Jacksonville, Florida</s2><s3>USA</s3><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Stoessl, Jon A" sort="Stoessl, Jon A" uniqKey="Stoessl J" first="Jon A." last="Stoessl">Jon A. Stoessl</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Pacific Parkinson's Research Centre</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Asymptomatic</term><term>Carrier</term><term>Dopamine</term><term>Mutation</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Positron emission tomography</term><term>Turnover</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Dopamine</term><term>Turnover</term><term>Asymptomatique</term><term>Mutation</term><term>Porteur</term><term>Tomographie par émission de positons</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Increase in dopamine (DA) turnover was found to occur early in symptomatic Parkinson's disease (PD) and to be functionally related to the dopamine transporter (DAT). The objectives of this study were to examine changes in DA turnover in the asymptomatic PD phase; to compare them with changes in other dopaminergic markers, and to investigate a possible relationship between DAT and DA turnover. Eight subjects from families at increased risk of PD due to LRRK2 mutation were investigated. Positron emission tomography imaging was performed with: <sup>18</sup>F-fluorodopa to determine the effective DA distribution volume (EDV), the inverse of DA turnover, and the DA uptake rate K<sub>occ</sub>, a marker of DA synthesis and storage; C-methylphenidate (MP, a DAT marker) and <sup>11</sup>C-dihydrotetrabenazine (DTBZ, a VMAT2 marker) to estimate the binding potentials BP<sub>ND_MP</sub> and BP<sub>ND_DTBZ</sub>. On average, EDV showed the largest reduction from age-matched control values (42%) followed by BP<sub>ND_MP</sub> (23%) and BP<sub>ND_DTBZ</sub> (17%), whereas K<sub>occ</sub> remained in the normal range for all subjects. No correlation was found between EDV and any other marker. DA turnover was found to be elevated in asymptomatic mutation carriers at increased risk of PD. Such change was determined to be larger than and statistically independent from changes observed with the other markers. These results support a compensatory role of increased DA turnover in presymptomatic disease and indicate that at this stage, in contrast to the symptomatic PD phase, increased turnover is not related to DAT.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>25</s2></fA05><fA06><s2>16</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Dopamine Turnover Increases in Asymptomatic LRRK2 Mutations Carriers</s1></fA08><fA11 i1="01" i2="1"><s1>SOSSI (Vesna)</s1></fA11><fA11 i1="02" i2="1"><s1>DE LA FUENTE-FERNANDEZ (Raul)</s1></fA11><fA11 i1="03" i2="1"><s1>NANDHAGOPAL (Ramachandiran)</s1></fA11><fA11 i1="04" i2="1"><s1>SCHULZER (Michael)</s1></fA11><fA11 i1="05" i2="1"><s1>MCKENZIE (Jessamyn)</s1></fA11><fA11 i1="06" i2="1"><s1>RUTH (Thomas J.)</s1></fA11><fA11 i1="07" i2="1"><s1>AASLY (Jan O.)</s1></fA11><fA11 i1="08" i2="1"><s1>FARRER (Matthew J.)</s1></fA11><fA11 i1="09" i2="1"><s1>WSZOLEK (Zbigniew K.)</s1></fA11><fA11 i1="10" i2="1"><s1>STOESSL (Jon A.)</s1></fA11><fA14 i1="01"><s1>Department of Physics and Astronomy, University of British Columbia</s1><s2>Vancouver British Columbia</s2><s3>CAN</s3><sZ>1 aut.</sZ></fA14><fA14 i1="02"><s1>Pacific Parkinson's Research Centre</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="03"><s1>TRIUMF</s1><s2>Vancouver, British Columbia</s2><s3>CAN</s3><sZ>6 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Neuroscience and Neurology, NTNU</s1><s2>Trondheim</s2><s3>NOR</s3><sZ>7 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Neuroscience, Mayo Clinic</s1><s2>Jacksonville, Florida</s2><s3>USA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Neurology, Mayo Clinic</s1><s2>Jacksonville, Florida</s2><s3>USA</s3><sZ>9 aut.</sZ></fA14><fA20><s1>2717-2723</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000193512620030</s5></fA43><fA44><s0>0000</s0><s1>© 2011 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>38 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>11-0065108</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Increase in dopamine (DA) turnover was found to occur early in symptomatic Parkinson's disease (PD) and to be functionally related to the dopamine transporter (DAT). The objectives of this study were to examine changes in DA turnover in the asymptomatic PD phase; to compare them with changes in other dopaminergic markers, and to investigate a possible relationship between DAT and DA turnover. Eight subjects from families at increased risk of PD due to LRRK2 mutation were investigated. Positron emission tomography imaging was performed with: <sup>18</sup>F-fluorodopa to determine the effective DA distribution volume (EDV), the inverse of DA turnover, and the DA uptake rate K<sub>occ</sub>, a marker of DA synthesis and storage; C-methylphenidate (MP, a DAT marker) and <sup>11</sup>C-dihydrotetrabenazine (DTBZ, a VMAT2 marker) to estimate the binding potentials BP<sub>ND_MP</sub> and BP<sub>ND_DTBZ</sub>. On average, EDV showed the largest reduction from age-matched control values (42%) followed by BP<sub>ND_MP</sub> (23%) and BP<sub>ND_DTBZ</sub> (17%), whereas K<sub>occ</sub> remained in the normal range for all subjects. No correlation was found between EDV and any other marker. DA turnover was found to be elevated in asymptomatic mutation carriers at increased risk of PD. Such change was determined to be larger than and statistically independent from changes observed with the other markers. These results support a compensatory role of increased DA turnover in presymptomatic disease and indicate that at this stage, in contrast to the symptomatic PD phase, increased turnover is not related to DAT.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B17G</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Dopamine</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Dopamine</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Dopamina</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Turnover</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Turnover</s0><s5>10</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Turnover</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Asymptomatique</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Asymptomatic</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Asintomático</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Mutation</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Mutation</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Mutación</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Porteur</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Carrier</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Portador</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Tomographie par émission de positons</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Positron emission tomography</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Tomografía emisión positrones</s0><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Catécholamine</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Catecholamine</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Catecolamina</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Neurotransmetteur</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Neurotransmitter</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Neurotransmisor</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>42</s5></fC07><fN21><s1>045</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Canada</li><li>Norvège</li><li>États-Unis</li></country><region><li>Floride</li><li>Trøndelag</li></region><settlement><li>Trondheim</li></settlement></list><tree><country name="Canada"><noRegion><name sortKey="Sossi, Vesna" sort="Sossi, Vesna" uniqKey="Sossi V" first="Vesna" last="Sossi">Vesna Sossi</name></noRegion><name sortKey="De La Fuente Fernandez, Raul" sort="De La Fuente Fernandez, Raul" uniqKey="De La Fuente Fernandez R" first="Raul" last="De La Fuente-Fernandez">Raul De La Fuente-Fernandez</name><name sortKey="Mckenzie, Jessamyn" sort="Mckenzie, Jessamyn" uniqKey="Mckenzie J" first="Jessamyn" last="Mckenzie">Jessamyn Mckenzie</name><name sortKey="Nandhagopal, Ramachandiran" sort="Nandhagopal, Ramachandiran" uniqKey="Nandhagopal R" first="Ramachandiran" last="Nandhagopal">Ramachandiran Nandhagopal</name><name sortKey="Ruth, Thomas J" sort="Ruth, Thomas J" uniqKey="Ruth T" first="Thomas J." last="Ruth">Thomas J. Ruth</name><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name><name sortKey="Stoessl, Jon A" sort="Stoessl, Jon A" uniqKey="Stoessl J" first="Jon A." last="Stoessl">Jon A. Stoessl</name></country><country name="Norvège"><region name="Trøndelag"><name sortKey="Aasly, Jan O" sort="Aasly, Jan O" uniqKey="Aasly J" first="Jan O." last="Aasly">Jan O. Aasly</name></region></country><country name="États-Unis"><region name="Floride"><name sortKey="Farrer, Matthew J" sort="Farrer, Matthew J" uniqKey="Farrer M" first="Matthew J." last="Farrer">Matthew J. Farrer</name></region><name sortKey="Wszolek, Zbigniew K" sort="Wszolek, Zbigniew K" uniqKey="Wszolek Z" first="Zbigniew K." last="Wszolek">Zbigniew K. Wszolek</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000368 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000368 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:11-0065108
|texte= Dopamine Turnover Increases in Asymptomatic LRRK2 Mutations Carriers
}}
| This area was generated with Dilib version V0.6.29. |  |